Justin Yorke Sells Shares of Processa Pharmaceuticals

Justin Yorke sold 203 shares of Processa Pharmaceuticals, Inc. (NasdaqCM: PCSA) on June 26, 2026. This transaction was not part of a pre-planned trading program.

Insider Buying and Selling at Processa Pharmaceuticals, Inc.

On June 26, 2026, multiple insiders were active in Processa Pharmaceuticals. Justin Yorke sold 203 shares, while James Neal, Khoso Baluch, and Geraldine Pannu each bought 203 shares. These transactions were not conducted under Rule 10b5-1 plans.

Other Institutional Activity in Processa Pharmaceuticals

Several institutional investors made moves in Processa Pharmaceuticals. Connective Capital Management, LLC opened a new position with 70,736 shares, valued at approximately $178,608. Stonepine Capital Management, LLC significantly increased its stake by 42,677 shares, now holding 55,000 shares worth about $138,875, marking a 346.3% increase. Geode Capital Management, LLC added 9,585 shares, bringing its total to 24,908 shares, valued at around $62,768, a 62.6% increase. UBS Group AG, however, reduced its holdings by 10,109 shares, leaving it with 2,531 shares valued at $6,391, an 80% decrease.

Processa Pharmaceuticals, Inc. Stock Down 6.3%

Shares of Processa Pharmaceuticals traded near $1.92 on Wednesday. The company has a market cap of approximately $5.15 million. Its forward P/E ratio is not meaningful as the company is not currently profitable. The stock's beta is 0.961, indicating average volatility compared to the market. Over the past year, the stock has ranged from a low of $1.76 to a high of $14.25. The 50-day moving average is $2.56, while the 200-day moving average is $4.23.

Analysts Set New Price Targets

On September 2, 2025, HC Wainwright & Co. maintained its buy rating for Processa Pharmaceuticals, setting a price target of $1.00. Earlier, on June 30, 2025, the same firm had also maintained a buy rating with a $2.00 target. The consensus among analysts is a buy rating with a target price of $2.00, based on multiple opinions.

About Processa Pharmaceuticals

Processa Pharmaceuticals, Inc. is a clinical-stage biotech company based in Vero Beach, Florida. It focuses on developing cancer therapies aimed at improving the safety and efficacy of existing treatments. The company's pipeline includes modifications of FDA-approved oncology drugs, such as NGC-Cap and NGC-Iri, targeting various types of cancer. Processa is also working on non-oncology drugs like PCS499 and PCS12852 for other medical conditions. Founded in 2015, the company operates within the healthcare sector and employs 12 people.

Bottom Line

Justin Yorke's recent sale of shares in Processa Pharmaceuticals highlights insider activity in the company. Investors often watch such transactions for potential insights, though they are not necessarily indicative of future performance. The company's stock has seen significant institutional interest, with some funds increasing their stakes. Analyst ratings remain positive, with recent price targets suggesting potential upside.